Biotechnology company · ARGX

argenx
clinical trial
pipeline

Registry checked

Published

Efgartigimod PH20 SC is linked to 14 distinct active studies, with 5 Phase 2, 8 Phase 3, 1 Phase 4. Empasiprubart is linked to 11 distinct active studies, with 2 Phase 1, 5 Phase 2, 4 Phase 3.

Phase 2 study NCT06284954 in Dermatomyositis and Myositis lists estimated primary completion in November 2026. Phase 3 study NCT04833894 in Generalized Myasthenia Gravis lists estimated primary completion in March 2027. These are registry estimates of primary completion, not confirmed results announcements or overall study completion.

Active trial mix

Lead-sponsor scope

43active trials
as lead sponsor
  • Phase 15
  • Phase 213
  • Phase 317
  • Phase 41
  • Phase not recorded7

One highest explicitly recorded phase per active trial. Combined phases use the highest phase. Phase not recorded is shown separately.

Change history

Follow the changes behind the company’s clinical programme.

30 Sept 2026 – 29 Oct 2026 · UTC

Recorded changes

84 trials30 completed days
Recruitment statusPrimary completionEnrolmentFirst observedOther

Highlighted changes 03

Select an example to see what changed

02Primary completion

Primary completion moved later

2026-10-01 (estimated)2027-10 (estimated)
01 Oct 2026Oct 2027

A Phase 3 Study to Evaluate the Safety and Efficacy of Efgartigimod PH20 Subcutaneous in Adult Patients With Primary Immune Thrombocytopenia

NCT04812925 · ClinicalTrials.gov
Recorded by ComplyRx
20 Oct 2026
Registry last updated
19 Oct 2026

Verified live registry-derived observations in completed UTC days. Recorded dates are observation dates, not necessarily registry amendment dates. Zero means no eligible observations recorded, not daily monitoring of every trial.

0 archive observations and 0 unverified observations excluded.

View exact daily values and type totals
Recorded observations in completed UTC days
Date (UTC)Recruitment statusPrimary completionEnrolmentFirst observedOtherTotalAffected trials
2026-09-300000000
2026-10-010000000
2026-10-020000000
2026-10-030000000
2026-10-040000000
2026-10-050000000
2026-10-060000000
2026-10-070000000
2026-10-080000000
2026-10-090000000
2026-10-100000000
2026-10-110000000
2026-10-120000000
2026-10-130000000
2026-10-140000000
2026-10-151110031
2026-10-161010021
2026-10-170000000
2026-10-180000000
2026-10-190000000
2026-10-200100121
2026-10-210000000
2026-10-220000000
2026-10-230000000
2026-10-240000000
2026-10-250000000
2026-10-260000000
2026-10-270000000
2026-10-281000011
2026-10-290000000
Type totals3220184 distinct

02 / Drugs & programmes

Explore the pipeline

5 selected programmes

Choose a drug to open its record in the tracker. Sign in to continue.

Efgartigimod PH20 SC

Canonical investigational asset

14
Active trials
4
Recruiting trials
Trial phases
Highest: Phase 4
  • Phase 10
  • Phase 25
  • Phase 38
  • Phase 41
  • Phase not recorded0
Studied condition
Active Idiopathic Inflammatory Myopathy · Antibody-mediated Rejection · Antisynthetase Syndrome
Next primary completion
Mar 2027 · estimated
Open drug

Empasiprubart

Canonical investigational asset

11
Active trials
5
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 12
  • Phase 25
  • Phase 34
  • Phase 40
  • Phase not recorded0
Studied condition
AChR-Ab Seropositive Generalized Myasthenia Gravis · Chronic Inflammatory Demyelinating Polyneuropathy · Chronic Inflammatory Demyelinating Polyradiculoneuropathy
Next primary completion
Nov 2026 · estimated
Open drug

Efgartigimod

Canonical investigational asset

6
Active trials
3
Recruiting trials
Trial phases
Highest: Phase 3
  • Phase 10
  • Phase 21
  • Phase 35
  • Phase 40
  • Phase not recorded0
Studied condition
AChR-Ab Seropositive Generalized Myasthenia Gravis · Generalized Myasthenia Gravis · Generalized Myasthenia Gravis (gMG)
Next primary completion
Mar 2027 · estimated
Open drug

Adimanebart

Canonical investigational asset

2
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 2
  • Phase 11
  • Phase 21
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
CMS · Congenital Myasthenic Syndrome · Spinal Muscular Atrophy (SMA)
Next primary completion
Not reported
Open drug

ARGX-124

Canonical investigational asset

1
Active trials
1
Recruiting trials
Trial phases
Highest: Phase 1
  • Phase 11
  • Phase 20
  • Phase 30
  • Phase 40
  • Phase not recorded0
Studied condition
Healthy Volunteers
Next primary completion
Not reported
Open drug

33 of 43 active trials have accepted investigational programme links. Trial context does not establish ownership or complete drug coverage.

5 selected programmes · accepted investigational links cover 33 of 43 active trials · brand names checked where available.

Accepted links do not establish complete intervention mapping or ownership. Programme populations overlap.

Up to six canonical assets identified through accepted investigational links in active trials. Counts describe this trial context and do not establish ownership or a complete corporate drug portfolio. Opening a record requires sign-in and does not start tracking.

03 / Clinical trial timeline

argenx trials in progress

Registry start → study completion

◇ Recorded observation│ Primary completion milestoneHatched ends retain month / year uncertaintyHover, focus or tap an observation
Trial / programme
6 selected Phase 3 / 2 trials
2021202220232024202520262027202820292030
empacific
Empasiprubart

NCT06284954

Phase 2 · Active, not recruiting

Trial source and qualifications

A Study to Evaluate Safety and Efficacy of Empasiprubart in Adults With Dermatomyositis

Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 3 inspected observations were not displayed.

3 candidate observations · 0 shown · 0 recorded after primary completion · 3 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

ClinicalTrials.gov source

3 inspected observations omitted. At most three verified observations are shown, not full history.

    Start: 20 Aug 2024 · actual
    Primary completion: Nov 2026 · estimated
    Study completion: Nov 2026 · estimated

    2021202220232024202520262027202820292030
    ADAPT Jr
    Efgartigimod

    NCT04833894

    Phase 3 · Active, not recruiting

    Trial source and qualifications

    Evaluating the Pharmacokinetics, Pharmacodynamics, and Safety of Efgartigimod Administered Intravenously in Children With Generalized Myasthenia Gravis

    Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 2 inspected observations were not displayed.

    2 candidate observations · 0 shown · 0 recorded after primary completion · 2 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

    ClinicalTrials.gov source

    2 inspected observations omitted. At most three verified observations are shown, not full history.

      Start: 26 Oct 2021 · actual
      Primary completion: Mar 2027 · estimated
      Study completion: Mar 2027 · estimated

      2021202220232024202520262027202820292030
      eSScape
      Efgartigimod PH20 SC

      NCT06655155

      Phase 2 · Active, not recruiting

      Trial source and qualifications

      A Study to Assess the Efficacy and Safety of Efgartigimod PH20 SC in Adults With Systemic Sclerosis

      Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

      3 candidate observations · 2 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      1 inspected observations omitted. At most three verified observations are shown, not full history.

      • status flip · Recorded 2026-10-16 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.
      • enrollment change · Recorded 2026-10-16 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

      Start: 11 Nov 2024 · actual
      Primary completion: Mar 2027 · estimated
      Study completion: Oct 2027 · estimated

      2021202220232024202520262027202820292030
      ADHERE+
      Efgartigimod PH20 SC

      NCT04280718

      Phase 2 · Active, not recruiting

      Trial source and qualifications

      A Study to Assess the Long-term Safety and Efficacy of a Subcutaneous Formulation of Efgartigimod in Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP, an Autoimmune Disorder That Affects the Peripheral Nerves)

      Duration ends at independently recorded study completion. Source date qualifications: start-clipped-at-horizon. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 1 inspected observations were not displayed.

      Start clipped at the display horizon.

      1 candidate observations · 0 shown · 0 recorded after primary completion · 1 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

      ClinicalTrials.gov source

      1 inspected observations omitted. At most three verified observations are shown, not full history.

        Start: 18 Sept 2020 · actual
        Primary completion: 30 Apr 2027 · estimated
        Study completion: 30 Apr 2027 · estimated

        2021202220232024202520262027202820292030
        Unity
        Efgartigimod PH20 SC

        NCT06684847

        Phase 3 · Active, not recruiting

        Trial source and qualifications

        A Study of the Efficacy and Safety of Efgartigimod in Patients With Primary Sjögren's Syndrome

        Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history. 4 inspected observations were not displayed.

        4 candidate observations · 0 shown · 0 recorded after primary completion · 4 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

        ClinicalTrials.gov source

        4 inspected observations omitted. At most three verified observations are shown, not full history.

          Start: 15 Jan 2025 · actual
          Primary completion: Jul 2027 · estimated
          Study completion: Jul 2028 · estimated

          2021202220232024202520262027202820292030
          ADAPT Jr SC
          Efgartigimod PH20 SC

          NCT06392386

          Phase 3 · Recruiting

          Trial source and qualifications

          A Study of Efgartigimod PH20 SC in Children Between 2 and Less Than 18 Years of Age With Generalized Myasthenia Gravis

          Duration ends at independently recorded study completion. Registry primary completion, not a confirmed results announcement. Observation markers describe recorded observations, not scheduled completion dates. Up to three newest eligible verified observations from a bounded trailing 24-month candidate window are shown, not full history.

          1 candidate observations · 1 shown · 0 recorded after primary completion · 0 unverified · 0 invalid dates · 0 before supported start · 0 outside horizon · 0 excluded by display cap · source retrieval not capped.

          ClinicalTrials.gov source

          Up to three verified eligible observations in the bounded history window.

          • pc date moved · Recorded 2026-09-14 · Verified live registry-derived observation. Recorded date is not necessarily the registry amendment date. Observations outside the duration bar do not extend the study.

          Start: 28 Jun 2024 · actual
          Primary completion: Sept 2027 · estimated
          Study completion: Sept 2027 · estimated

          2021202220232024202520262027202820292030

          Up to six active Phase 2/3 trials with upcoming estimated primary-completion intervals, ordered by nearest interval, highest phase and NCT. Historical dates never pad this selection. Ten calendar years are shown. Dates retain registry precision and independent date types.

          6 selected of 26 eligible trials · 0 without supported dates · 0 omitted for contradictory chronology. Excluded: 3 actual primary completions, 0 untyped primary completions, 1 past estimates, 0 outside the horizon, 0 contradictory dates.

          04 / Therapeutic focus

          Where the activity is

          18

          active trials in Neurology

          Primary therapeutic groups are indexed enrichment. Unmapped trials and healthy volunteers remain in the active-trial denominator.

          Active trials by primary therapeutic area

          • Neurology18 trials
          • Immunology & Inflammation5 trials
          • Haematology3 trials
          • Metabolic/Endocrine/Nutrition2 trials
          • Anaesthesia & Perioperative Care1 trials
          • Renal & Urology1 trials
          • Unmapped10 trials
          • Healthy volunteers3 trials

          Each active trial counts once. Full bar equals all active trials in this lead-sponsor scope. This grouping does not describe commercial strategy.

          06 / Related companies

          All companies

          No supported overlap was identified in the selected programme context. Based on the selected programmes and indexed lead-sponsor records, not a complete ranking or a competitive/ownership assessment.

          Sources, scope and methodology

          ClinicalTrials.gov lead-sponsor scope

          Canonical current-owner attribution covers 87 distinct NCT records attributed through the canonical sponsor map. Included canonical entities: argenx. Phrases retrieve candidates only, then verbatim lead-sponsor attribution determines inclusion.

          ClinicalTrials.gov

          Attribution coverage

          87 distinct registry candidates produced 87 accepted studies. 0 mapped to other owners, 0 lacked a canonical mapping and 0 fell outside an operating subset. Accepted mappings include 87 unverified, 0 identity-only and 0 device-tagged trial memberships. Mapping flags describe evidence quality, not a separate ownership authority.

          Indexed enrichment

          79 scoped records have indexed enrichment and 8 do not. Missing enrichment does not remove a trial from cohort counts.

          Scope observation

          The successful attribution check completed at 2026-10-30T22:59:21.904Z. This is a dated canonical-attribution snapshot. Static pages normally regenerate after 24 hours, but cached HTML can outlive that interval when regeneration fails. Map changes affect the next successful regeneration. This timestamp is separate from individual registry-update dates. Snapshot ee3403563b2acffdd30407e2b1a95e861243b6244c7790bbc4b53f718ff95eac.

          Active means recruiting, not yet recruiting, active not recruiting or enrolling by invitation. Recruiting counts recruiting only. Trial counts describe lead sponsorship under the published canonical-attribution policy. Identified programmes and therapeutic groups depend on available enrichment. Drug, device and other clinical studies may be included. This is the mapped company scope, not an exhaustive corporate trial census.

          Dated canonical-attribution snapshot: 87 mapped lead-sponsored clinical studies across all statuses. 79 have indexed enrichment, 8 do not. Drug, device and other studies may be represented. Sponsor tags do not classify trial interventions. This is the mapped company scope, not an exhaustive corporate trial census. Recorded changes may reflect observation or archive ingestion rather than a new registry amendment.

          Keep following
          what matters.

          Choose the drugs, companies or disease areas you follow. Bring trial changes and upcoming readouts into one watch.

          Build your watch

          Choose what to track in the watch builder.